Compared side by side
CJC-1295 with DAC vs CJC-1295 no DAC: how they differ
Reviewed How we check the library
The short answer
Both are GHRH analogues; the difference is the DAC (Drug Affinity Complex), which stretches CJC-1295’s half-life to about a week. With DAC, one weekly injection keeps GH and IGF-1 raised for days while natural pulses continue; without it (also sold as Mod GRF 1-29), the short action gives pulse-like GH release, taken 2–3 times a day. The no-DAC form is almost always stacked with ipamorelin.
Side by side
| Compared | CJC-1295 with DAC | CJC-1295 no DAC |
|---|---|---|
| Category | Growth hormone | Growth hormone |
| Also known as | CJC-1295 DAC, DAC:GRF | Modified GRF 1-29, Mod GRF 1-29, CJC-1295 without DAC |
| What it is | A long-acting growth hormone releasing hormone analogue: the DAC modification extends its half-life to about a week, so one weekly injection keeps GH and IGF-1 raised, lifting baseline GH while natural pulses continue. | The shorter-acting version of CJC-1295, meant to give sharp, pulse-like GH release. |
| How it works | GHRH analogue with Drug Affinity Complex that extends half-life to about a week. In human studies one injection raised baseline GH and IGF-1 for days while natural GH pulses continued; recovery, body-composition and sleep effects are extrapolated from GH physiology and user reports. Weekly dosing protocol. | GHRH analogue without the DAC modification. Its half-life in people hasn't been measured (native GHRH lasts minutes), and the short action gives pulse-like GH release. Usually stacked with Ipamorelin to mimic natural GH secretion patterns. |
| Commonly reported | Water retention and puffiness, sometimes tingling hands, over the first weeks, and tiredness in the days after the shot. Its human data are two small phase 1 studies; it was never approved. | A flush or head rush within minutes of injecting, deeper sleep and vivid dreams early on, and mild water retention over the weeks. The no-DAC form itself has no published human studies. |
| Studied range | Research range: 1–2 mg. Studied in research — not a recommendation. | Research range: 100–200 mcg. Studied in research — not a recommendation. |
| How often | Weekly | 2–3x daily |
| Half-life | ~6–8 days (measured in healthy adults: 5.8–8.1 days) | ~30 min (community estimate; not measured in people: sermorelin, the unmodified 1-29 chain, lasts 11–12 minutes) |
| Route | SubQ injection | SubQ injection |
| Typical run | 8–12 weeks common. Weekly dosing means effects accumulate — give adequate time off between cycles. | 8–12 weeks typical. Usually stacked with Ipamorelin; cycle both together. |
| Evidence | Moderate: animal studies + some human data | Moderate: animal studies + some human data |
| Common side effects | Water retention, headache, flushing, injection site pain, fatigue, carpal tunnel symptoms | Water retention, headache, flushing, injection site pain |
- Category
- CJC-1295 with DACGrowth hormone
- CJC-1295 no DACGrowth hormone
- Also known as
- CJC-1295 with DACCJC-1295 DAC, DAC:GRF
- CJC-1295 no DACModified GRF 1-29, Mod GRF 1-29, CJC-1295 without DAC
- What it is
- CJC-1295 with DACA long-acting growth hormone releasing hormone analogue: the DAC modification extends its half-life to about a week, so one weekly injection keeps GH and IGF-1 raised, lifting baseline GH while natural pulses continue.
- CJC-1295 no DACThe shorter-acting version of CJC-1295, meant to give sharp, pulse-like GH release.
- How it works
- CJC-1295 with DACGHRH analogue with Drug Affinity Complex that extends half-life to about a week. In human studies one injection raised baseline GH and IGF-1 for days while natural GH pulses continued; recovery, body-composition and sleep effects are extrapolated from GH physiology and user reports. Weekly dosing protocol.
- CJC-1295 no DACGHRH analogue without the DAC modification. Its half-life in people hasn't been measured (native GHRH lasts minutes), and the short action gives pulse-like GH release. Usually stacked with Ipamorelin to mimic natural GH secretion patterns.
- Commonly reported
- CJC-1295 with DACWater retention and puffiness, sometimes tingling hands, over the first weeks, and tiredness in the days after the shot. Its human data are two small phase 1 studies; it was never approved.
- CJC-1295 no DACA flush or head rush within minutes of injecting, deeper sleep and vivid dreams early on, and mild water retention over the weeks. The no-DAC form itself has no published human studies.
- Studied range
- CJC-1295 with DACResearch range: 1–2 mg. Studied in research — not a recommendation.
- CJC-1295 no DACResearch range: 100–200 mcg. Studied in research — not a recommendation.
- How often
- CJC-1295 with DACWeekly
- CJC-1295 no DAC2–3x daily
- Half-life
- CJC-1295 with DAC~6–8 days (measured in healthy adults: 5.8–8.1 days)
- CJC-1295 no DAC~30 min (community estimate; not measured in people: sermorelin, the unmodified 1-29 chain, lasts 11–12 minutes)
- Route
- CJC-1295 with DACSubQ injection
- CJC-1295 no DACSubQ injection
- Typical run
- CJC-1295 with DAC8–12 weeks common. Weekly dosing means effects accumulate — give adequate time off between cycles.
- CJC-1295 no DAC8–12 weeks typical. Usually stacked with Ipamorelin; cycle both together.
- Evidence
- CJC-1295 with DACModerate: animal studies + some human data
- CJC-1295 no DACModerate: animal studies + some human data
- Common side effects
- CJC-1295 with DACWater retention, headache, flushing, injection site pain, fatigue, carpal tunnel symptoms
- CJC-1295 no DACWater retention, headache, flushing, injection site pain
Typical run: Community practice — opinions vary. Not a clinical recommendation.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
CJC-1295 with DAC
- Day 1–14 GH is building; water retention is common
- Day 14–42 Recovery and skin quality are changing
- Day 42–84 Peak recomp — watch for carpal tunnel
CJC-1295 no DAC
- Day 1–14 Sleep usually moves first
- Day 14–28 Recovery is quicker, skin looks better
- Day 28–56 Body composition starts shifting
- Day 56–84 Cycle endpoint
Questions people ask
How long do CJC-1295 with DAC and CJC-1295 no DAC last?
The half-life of CJC-1295 with DAC is ~6–8 days (measured in healthy adults: 5.8–8.1 days). The half-life of CJC-1295 no DAC is ~30 min (community estimate; not measured in people: sermorelin, the unmodified 1-29 chain, lasts 11–12 minutes).
How often are CJC-1295 with DAC and CJC-1295 no DAC taken?
CJC-1295 with DAC: weekly. Route: SubQ injection. CJC-1295 no DAC: 2–3x daily. Route: SubQ injection.
How are CJC-1295 with DAC and CJC-1295 no DAC dosed in research?
The research range for CJC-1295 with DAC is 1–2 mg. The research range for CJC-1295 no DAC is 100–200 mcg. Studied in research — not a recommendation.
What are the common side effects of CJC-1295 with DAC and CJC-1295 no DAC?
For CJC-1295 with DAC, the library lists: water retention, headache, flushing, injection site pain, fatigue, carpal tunnel symptoms. For CJC-1295 no DAC: water retention, headache, flushing, injection site pain.
Each one in full
PepVault for iPhone
Track either one in PepVault
Log every dose of CJC-1295 with DAC or CJC-1295 no DAC, with reminders on your schedule. 7 days free on the yearly plan for new subscribers.
